ABBV vs ADBE Stock Comparison

Scores Breakdown

Metric	ABBV	ADBE
📈 Growth	26/30	22/30
💰 Profitability	18/20	17/20
🏦 Financial Health	6/20	16/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	8/10	4/10
Overall Score	64/100	73/100

Side-by-Side Summaries

ABBV Analysis	ADBE Analysis
📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2). 💰 Margins & Cash Flow Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters. 🛡️ Balance Sheet & Liquidity Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations. ⚠️ Key Drivers & Risks Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power. Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.	📈 Growth & Financial Trajectory Over 8 quarters, revenue rose from $5.714B (Q2 2024) to $6.618B (Q2 2026), up about 16%. Net income grew from $1.712B to $1.889B, with quarterly fluctuations but an overall positive trend. 💰 Margins & Cash Flow Gross margin stays in the high 80s to low 90s% (examples: Q4 2025 around 92%, Q2 2026 around 89%). Operating income remains solid near $2.0–$2.3B per quarter. Net cash flow from operating activities is consistently positive, typically around $2.2B–$3.2B per quarter, with occasional stronger quarter (e.g., Q4 2025, $3.16B). Investing/financing flows are mixed but liquidity strong. 🛡️ Balance Sheet & Liquidity Cash balances range roughly $5.6B–$7.0B; total assets around $28–$30B; current liabilities in the $9–12B range; long-term debt about $4–$6B; equity around $11.4–$11.8B. Leverage moderate; liquidity ample. ⚠️ Key Drivers & Risks Drivers: AI-enabled product enhancements and sustained Creative Cloud/enterprise demand. Risks: Valuation sensitivity to growth trajectory and potential macro swings in end-market demand.

ABBV Analysis

ADBE Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over 8 quarters, revenue rose from $5.714B (Q2 2024) to $6.618B (Q2 2026), up about 16%. Net income grew from $1.712B to $1.889B, with quarterly fluctuations but an overall positive trend.

💰 Margins & Cash Flow

Gross margin stays in the high 80s to low 90s% (examples: Q4 2025 around 92%, Q2 2026 around 89%). Operating income remains solid near $2.0–$2.3B per quarter. Net cash flow from operating activities is consistently positive, typically around $2.2B–$3.2B per quarter, with occasional stronger quarter (e.g., Q4 2025, $3.16B). Investing/financing flows are mixed but liquidity strong.

🛡️ Balance Sheet & Liquidity

Cash balances range roughly $5.6B–$7.0B; total assets around $28–$30B; current liabilities in the $9–12B range; long-term debt about $4–$6B; equity around $11.4–$11.8B. Leverage moderate; liquidity ample.

⚠️ Key Drivers & Risks

Drivers: AI-enabled product enhancements and sustained Creative Cloud/enterprise demand.
Risks: Valuation sensitivity to growth trajectory and potential macro swings in end-market demand.

Similar Companies

ABT Score: 71 AMGN Score: 67 BMY Score: 72 GILD Score: 46 JNJ Score: 86 LLY Score: 82 MRK Score: 58 MRNA Score: 38 PFE Score: 55

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"